Treating the patient and not just the cancer: therapeutic burden in prostate cancer

[1]  T. Tammela,et al.  Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. , 2020, The New England journal of medicine.

[2]  F. Saad,et al.  Apalutamide and Overall Survival in Prostate Cancer. , 2020, European urology.

[3]  F. Saad,et al.  Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[4]  T. Tammela,et al.  Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). , 2020 .

[5]  F. Saad,et al.  Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). , 2020 .

[6]  Steven C. R. Williams,et al.  Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers. , 2020 .

[7]  World Population Ageing 2019 Highlights , 2019 .

[8]  A. Morgans,et al.  A review of prostate cancer treatment impact on the CNS and cognitive function , 2019, Prostate Cancer and Prostatic Diseases.

[9]  Michaela Bairlein,et al.  Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies , 2019, European Journal of Drug Metabolism and Pharmacokinetics.

[10]  T. Tammela,et al.  Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial , 2019, Targeted Oncology.

[11]  L. Weissbach,et al.  Prostate-specific health-related quality of life and patient-physician communication - A 3.5-year follow-up. , 2019, Patient education and counseling.

[12]  P. Barata,et al.  Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide , 2019, Cancer management and research.

[13]  T. Tammela,et al.  Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC). , 2019, Journal of Clinical Oncology.

[14]  F. Saad,et al.  Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT). , 2019, Journal of Clinical Oncology.

[15]  A. Hussain,et al.  The evolving role of diet in prostate cancer risk and progression , 2019, Current opinion in oncology.

[16]  Prashanth Rawla,et al.  Epidemiology of Prostate Cancer , 2019, World journal of oncology.

[17]  F. Saad,et al.  Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. , 2019, The Lancet. Oncology.

[18]  Steven L. Chang,et al.  Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Tammela,et al.  Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer , 2019, The New England journal of medicine.

[20]  W. Oyen,et al.  Managing Nonmetastatic Castration-resistant Prostate Cancer. , 2019, European urology.

[21]  Jianlin Liu,et al.  The hidden patient: chronic physical morbidity, psychological distress, and quality of life in caregivers of older adults , 2018, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.

[22]  F. Saad,et al.  Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. , 2018, The Lancet. Oncology.

[23]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[24]  Fang Yang,et al.  Prevalence and determinants of depression in caregivers of cancer patients , 2018, Medicine.

[25]  G. Naglie,et al.  Impact of Androgen Deprivation Therapy on Self‐Reported Cognitive Function in Men with Prostate Cancer , 2018, The Journal of urology.

[26]  F. Saad,et al.  Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.

[27]  A. Vickers,et al.  Comparison of Physician-Documented Versus Patient-Reported Collection of Comorbidities Among Patients With Prostate Cancer Upon First Visit to the Urology Clinic. , 2018, JCO clinical cancer informatics.

[28]  H. Kantarjian,et al.  The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment , 2018, CA: a cancer journal for clinicians.

[29]  S. Sandmann,et al.  Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography. , 2018 .

[30]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[31]  L. Holmberg,et al.  Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  C. Moore,et al.  Patient‐reported outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments , 2017, BJU international.

[33]  M. Aapro,et al.  Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. , 2017, European urology.

[34]  James O Peabody,et al.  Establishment of a Web-based System for Collection of Patient-reported Outcomes After Radical Prostatectomy in a Statewide Quality Improvement Collaborative. , 2017, Urology.

[35]  R. Newton,et al.  Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial. , 2017, European urology.

[36]  M. Herdman,et al.  Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial , 2017, Health and Quality of Life Outcomes.

[37]  Matthew R. Cooperberg,et al.  Epidemiology of prostate cancer , 2017, World Journal of Urology.

[38]  N. Dawson,et al.  Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy. , 2017, American health & drug benefits.

[39]  R. Danesi,et al.  The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. , 2017, Cancer treatment reviews.

[40]  Richard M. Martin,et al.  The provision of dietary and physical activity advice for men diagnosed with prostate cancer: a qualitative study of the experiences and views of health care professionals, patients and partners , 2017, Cancer Causes & Control.

[41]  M. Donnelly,et al.  Cognitive impairment among prostate cancer patients: An overview of reviews , 2017, European journal of cancer care.

[42]  M. Ratain,et al.  Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) , 2016, Cancer.

[43]  P. Galan,et al.  Effect of Multimorbidity on Health-Related Quality of Life in Adults Aged 55 Years or Older: Results from the SU.VI.MAX 2 Cohort , 2016, PloS one.

[44]  U. Sambamoorthi,et al.  Association between Types of Chronic Conditions and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Prostate Cancer. , 2016, Population health management.

[45]  Tanya K. Day,et al.  Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. , 2016, Endocrine-related cancer.

[46]  L. Fallowfield,et al.  Patient-reported outcome measures of the impact of cancer on patients’ everyday lives: a systematic review , 2016, Journal of Cancer Survivorship.

[47]  I. Kawachi,et al.  Diverse Cumulative Impact of Chronic Diseases on Physical Health-Related Quality of Life: Implications for a Measure of Multimorbidity. , 2016, American journal of epidemiology.

[48]  T. Beer,et al.  Treatment of Nonmetastatic Castration-Resistant Prostate Cancer. , 2016, Oncology.

[49]  A. Hinz,et al.  Assessment of depression severity with the PHQ-9 in cancer patients and in the general population , 2016, BMC Psychiatry.

[50]  A. Armstrong,et al.  Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  Nolwenn Poquet,et al.  The Brief Pain Inventory (BPI). , 2016, Journal of physiotherapy.

[52]  M. D. de Ruiter,et al.  Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. , 2015, Journal of pain and symptom management.

[53]  L. Ercoli,et al.  Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial , 2015, Psycho-oncology.

[54]  J. Palvimo,et al.  Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies , 2015, Scientific Reports.

[55]  Keith A. Johnson,et al.  Functional Activities Questionnaire Items that Best Discriminate and Predict Progression from Clinically Normal to Mild Cognitive Impairment. , 2015, Current Alzheimer research.

[56]  C. Evans,et al.  Mechanisms of resistance in castration-resistant prostate cancer (CRPC) , 2015, Translational andrology and urology.

[57]  A. D'Amico,et al.  Adverse effects of androgen deprivation therapy and strategies to mitigate them. , 2015, European urology.

[58]  J. A. Bennett,et al.  Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. , 2015, Archives of physical medicine and rehabilitation.

[59]  C. Jansen,et al.  Evidence-based interventions for cancer- and treatment-related cognitive impairment. , 2014, Clinical journal of oncology nursing.

[60]  Paul O’Donohoe,et al.  Capturing Patient-Reported Outcome (PRO) Data Electronically: The Past, Present, and Promise of ePRO Measurement in Clinical Trials , 2014, The Patient - Patient-Centered Outcomes Research.

[61]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[62]  K. Cooney,et al.  Prostate cancer in young men: an important clinical entity , 2014, Nature Reviews Urology.

[63]  B. Bajorek,et al.  Defining ‘elderly’ in clinical practice guidelines for pharmacotherapy , 2014, Pharmacy practice.

[64]  Sharyl J. Nass,et al.  Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis , 2014 .

[65]  S. Willis,et al.  A randomized trial of cognitive rehabilitation in cancer survivors. , 2013, Life sciences.

[66]  S. Chevalier,et al.  Direct cost for initial management of prostate cancer: a systematic review. , 2013, Current oncology.

[67]  A. Fiorentino,et al.  Impact of comorbidity in elderly prostate cancer patients treated with brachytherapy. , 2013, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[68]  M. Levine.  Modeling the rate of senescence: can estimated biological age predict mortality more accurately than chronological age? , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.

[69]  John T. Wei,et al.  Partners’ Long-term Appraisal of Their Caregiving Experience, Marital Satisfaction, Sexual Satisfaction, and Quality of Life 2 Years After Prostate Cancer Treatment , 2013, Cancer nursing.

[70]  H. Scher,et al.  Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer , 2013, Cancer journal.

[71]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[72]  C. May,et al.  Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study , 2012, Patient related outcome measures.

[73]  A. Shukla,et al.  Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis , 2012, Journal of cancer epidemiology.

[74]  D. Cella,et al.  Comparison of FACT- and EQ-5D-based utility scores in cancer. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[75]  Karen R. Sepucha,et al.  Decision making about surgery for early-stage breast cancer. , 2012, Journal of the American College of Surgeons.

[76]  M. Stokes,et al.  Lifetime economic burden of prostate cancer , 2011, BMC health services research.

[77]  C. Ritchie,et al.  Multimorbidity: an issue of growing importance for oncologists. , 2011, Journal of oncology practice.

[78]  Christopher U. Jones,et al.  Radiotherapy and short-term androgen deprivation for localized prostate cancer. , 2011, The New England journal of medicine.

[79]  T. Ahles,et al.  International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. , 2011, The Lancet. Oncology.

[80]  F. Mair,et al.  Understanding Patients’ Experiences of Treatment Burden in Chronic Heart Failure Using Normalization Process Theory , 2011, The Annals of Family Medicine.

[81]  C. Shapiro,et al.  Brief Pain Inventory (BPI) , 2011 .

[82]  David S Knopman,et al.  Utility of the Functional Activities Questionnaire for Distinguishing Mild Cognitive Impairment From Very Mild Alzheimer Disease , 2010, Alzheimer disease and associated disorders.

[83]  P. Ubel,et al.  Deficits and Variations in Patients’ Experience with Making 9 Common Medical Decisions: The DECISIONS Survey , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[84]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[85]  Carl May,et al.  We need minimally disruptive medicine , 2009, BMJ : British Medical Journal.

[86]  R. Newton,et al.  Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation , 2009, Prostate Cancer and Prostatic Diseases.

[87]  C. Nelson,et al.  Cognitive effects of hormone therapy in men with prostate cancer , 2008, Cancer.

[88]  E. van Rossum,et al.  Feelings of anxiety and symptoms of depression in community-living older persons who avoid activity for fear of falling. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[89]  R. Newton,et al.  Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer , 2007, Prostate Cancer and Prostatic Diseases.

[90]  Hajime Orimo,et al.  [Reviewing the definition of elderly]. , 2006, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[91]  A. Zaslavsky,et al.  Patients' perceptions of quality of care for colorectal cancer by race, ethnicity, and language. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  G. Naglie,et al.  The association between patient age and prostate cancer stage and grade at diagnosis , 2004, BJU international.

[93]  C. Heinlein,et al.  Androgen receptor in prostate cancer. , 2004, Endocrine reviews.

[94]  H. Okamura,et al.  Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. , 2000, Journal of pain and symptom management.

[95]  William D. Kalsbeek,et al.  BOARD ON HEALTH CARE SERVICES INSTITUTE OF MEDICINE , 1999 .

[96]  Margaret Edmunds,et al.  BOARD ON HEALTH CARE SERVICES INSTITUTE OF MEDICINE , 1998 .

[97]  D. Cella,et al.  Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. , 1997, Journal of pain and symptom management.

[98]  J. Trapman,et al.  The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.

[99]  R. C. Macridis.  A review , 1963 .